Matthew Gumbleton, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Patent
    Ineligible company:
    Alterna Therapeutics
    Topic:
    SHIP1 inhibitors for modulating NK cell self-tolerance
    Date added:
    05/09/2024
    Date updated:
    05/09/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    MJH Lifesciences
    Topic:
    Discuss highlighted lung cancer abstracts presented at ESMO
    Date added:
    05/09/2024
    Date updated:
    05/09/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    OMNI Health Media
    Topic:
    Presented interesting clinical cases
    Date added:
    05/09/2024
    Date updated:
    05/09/2024
Return to Best of ASCO 2024, Boise